Biosimilar insulin: the current landscape
Since insulin was isolated in 1922, its production has continued to evolve, more recently with the ‘incremental innovation’ of insulin analogues with improved pharmacodynamic and pharmacokinetic profiles. The approval of Abasaglar, biosimilar glargine insulin, marks the latest development in insulin therapy. The present article reviews the current biosimilar landscape including manufacture, regulation, safety and prescribing issues.
Andrea Llano, Miles Fisher and Gerry McKay

Drug development and licensing in diabetes
The drug development process is long and expensive. Regulatory approval is granted following assessment of efficacy and safety, and drugs intended for use in the treatment of type 2 diabetes are also required to demonstrate cardiovascular safety.
Andrea Llano, Miles Fisher and Gerry McKay

Diabetes and ‘The Happiest Place on Earth’: safely attending an amusement park and riding roller coasters
People with type 1 diabetes need to be aware of the potential impact of rapidly changing physical forces that occur during a roller coaster ride and other environmental factors that can impact on an individual’s efforts to maintain optimal glycaemic control during a visit to an amusement park.
Katie Tovar, Jordan E Pinsker and David Kerr

Setting occupational standards for insulin-treated diabetes at sea, on land and in the air
Diabetes, particularly treatment with insulin, has proved a longstanding and frustrating barrier to employment in certain occupations where public safety has been deemed to be potentially at risk.
Ken Shaw

New insulins for diabetes
Diabetes treatments have come a long way, but continual efforts are needed to make the disease easier to manage and more affordable. Nearly half a million patients in the UK are prescribed insulin; however, despite insulin’s increasing use, current licensed insulin products incur significant barriers, which have fuelled the need to develop novel insulins and drug delivery methods.
Jason Seewoodhary and Stephen Phooi Yew Wong

Overview of complementary and alternative medicine and diabetes
People with diabetes frequently use complementary and alternative medicine (CAM) and other non-medicine CAM therapies, often combine various CAMs, and combine CAMs with conventional care.
Trisha Dunning

Evaluating diabetes integrated care pathways
The delivery of chronic disease care within new models of integration is an increasing reality. Currently, there is no clear evidence that community or tiered systems of care delivery are superior to existing diabetes services in terms of hard outcomes; however, it is apparent that they offer other potential benefits that can enhance the system of care.
Paul Grant and Ifyunaya Chika-Ezerioha

Transitional care for young people with diabetes: a national registry is urgently needed
Young people with diabetes require specialised and personalised care as they make the transition from children’s services to adult services. Getting the right care at this stage of their lives gives them the best chance of avoiding longer-term complications and remaining within the health service.
Rustam Rea

Management of diabetes within a secure environment
Many people situated in a wide variety of environments are affected by diabetes. The secure environment, of which prison is one, is an area in which the care and management of diabetes have been currently identified as being quite variable in terms of practice.
Keith Booles

The impact of pre-diabetes diagnosis on behaviour change: an integrative literature review
Type 2 diabetes is a growing global problem that not only affects individuals but also has an impact upon the economic health of countries. The number of people developing type 2 diabetes can be reduced by up to by 80%; this can be achieved by targeting those who are ‘at risk’.
W Youngs, WP Gillibrand and S Phillips

Web design and marketing agency Leamington Spa